Moderna Phase 3 success reframes cancer vaccine platform case

NeoOmni Atlas: an integrated database for pan-cancer neoantigen derived from proteogenomics analysis

A preprint describes NeoOmni Atlas, a pan-cancer T-cell epitope database built via proteogenomic reanalysis of 7,561 immunopeptidomics datasets (511 million raw spectra from 2,341 samples across 26 cancer types), yielding 872,414 eluted canonical and 198,961 non-canonical peptides across 18 molecular alteration classes, plus 759,386 unique ligands presented by 322 HLA alleles. A computational tumor-specific filtering framework identified 316,126 tumor-associated and 61,231 tumor-specific epitopes, with the tumor-specific set showing stronger predicted HLA class I A/B binding affinity, and 65 conserved tumor-specific epitopes recurrent across more than 10 tumors. Why it matters: mass-spectrometry-validated, non-canonical-inclusive target catalogs at this scale — including 369,781 novel ligands and 60 additional HLA alleles versus existing repositories — give vaccine developers and ML teams a ground-truth resource for target prioritization and model training.